Studies from serum samples could transform our understanding of the spread of COVID-19, but what antibodies alone say about immunity is not yet clear.

A small study of macaques finds they don’t develop a coronavirus infection the second time they are exposed, supporting the idea of using plasma from recovered patients as a treatment for COVID-19.

The 2019 Lasker medical and research awards celebrate advances in scientists’ understanding of T and B cells, Herceptin antibodies for treating breast cancer, and vaccine coverage around the globe.

A rogue hybrid lymphocyte, bearing characteristics of both B and T cells, may play a role in driving autoimmunity in the disease, although the mechanism is far from clear.

In line with previous research, a new study in mice demonstrates that B cells can be engineered to ward off infections, this time against respiratory syncytial virus (RSV).

An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.

Researchers report they’ve found a way to restore immune function in infants with one form of “bubble boy disease.”

Type I interferon organizes several immune mechanisms to suppress B cell responses to a chronic viral infection.

Gut bacteria in mice spur regulatory B cells to differentiate and release an anti-inflammatory cytokine.